Ascletis Licenses Medivir HCV Drug Candidate for Greater China

04:22 EDT 18 Aug 2017 | Genetic Engineering News

Ascletis negotiated rights to develop Medivir’s MIV-802 nucleotide polymerase inhibitor candidate for hepatitis C virus (HCV) therapy, for development in the greater China region, including mainland China, Hong Kong, Macau and Taiwan. Financial details were not disclosed, other than to confirm that Medivir will receive an upfront payment, plus development and commercialization milestones, and tiered royalties of marketed products containing MIV-802. Ascletis will fund and carry out all MIV-802 clinical development, manufacturing and commercialization activities for its designated territories.  MIV-802 is a nucleotide-based NS5B polymerase inhibitor, which has been designed to selectively target the liver. In August 2016 Trek Therapeutics acquired exclusive rights to develop and commercialize the drug globally, excluding the greater China region. Medivir’s former subsidiary, BioPhausia, which is now part of Karo Pharma, holds option rights to commercialize MIV-802-containing products in the Nordic countries and other specified Western European countries. Ascletis is focused on ...

Original Article: Ascletis Licenses Medivir HCV Drug Candidate for Greater China


More From BioPortfolio on "Ascletis Licenses Medivir HCV Drug Candidate for Greater China"

Quick Search


Relevant Topics

Polymerase Chain Reaction (PCR)
PCR (Polymerase Chain Reaction) uses the ability of DNA polymerase (enzymes that create DNA molecules by assembling nucleotides, the building blocks of DNA. These enzymes are essential to DNA replication and usually work in pairs to create two ident...

Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...